AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Aspira Women's Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.22−0.01 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
Aspira Women's Health Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | – | $8.90M | $9.22M | $9.34M | $9.29M | $9.31M | $9.18M | $8.96M | $8.92M | $8.99M | $9.15M | $9.10M | – | – |
| Genetics [Member] | – | – | – | – | – | – | – | – | – | – | $1.00K | $74.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Aspira Women's Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.